QR код

Development of AGT-7: An Innovative <sup>99m</sup>Tc-Labeled Theranostic Platform for Glioblastoma Imaging and Therapy

<b>Background</b>: Glioblastoma, the most common malignant primary brain tumor in adults, continues to present a major therapeutic challenge, with a median survival of only 12–15 months and a 5-year survival rate below 2%. Despite aggressive treatment—including maximal surgical excision, radiation,...

Повний опис

Збережено в:
Автори: Stavroula G. Kyrkou, Vasileios-Panagiotis Bistas, Evangelia-Alexandra Salvanou, Timothy Crook, Maria Giannakopoulou, Vasiliki Zoi, Maximos Leonardos, Andreas Fotopoulos, Chrissa Sioka, Ioannis Leonardos, George A. Alexiou, Penelope Bouziotis, Andreas G. Tzakos
Формат: Artigo
Мова:Inglês
Опубліковано: MDPI AG 2025-08-01
Серія:Pharmaceuticals
Предмети:
glioblastoma
Tetrofosmin
temozolamide
theranostics
technetium-99m molecular imaging
SPECT
Онлайн доступ:https://www.mdpi.com/1424-8247/18/8/1175
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси